Latest Conference Articles

December 8th 2016, 3:50am

San Antonio Breast Cancer Symposium

Extending letrozole therapy in women with early-stage, HR-positive breast cancer who completed 5 years of prior hormone therapy did not yield a statistically significant improvement in either disease-free or overall survival, but prolonged use of the aromatase inhibitor may be beneficial in some subgroups of women with a higher risk of recurrence.

December 8th 2016, 3:39am

San Antonio Breast Cancer Symposium

The genomic landscape of recurrent metastatic estrogen receptor–positive breast cancer differed significantly from the mutational profile of primary disease in a study that sheds light on acquired resistance mechanisms to anticancer therapies.

December 8th 2016, 1:51am

IASLC World Conference on Lung Cancer

Durvalumab treatment in the second-line setting or beyond demonstrated clinical benefit and led to durable responses in heavily pretreated patients with locally advanced or metastatic non-small cell lung cancer.

December 8th 2016, 12:24am

San Antonio Breast Cancer Symposium

Adding the PARP inhibitor veliparib to carboplatin/paclitaxel chemotherapy induced a response rate of 77.8% in patients with advanced BRCA-positive breast cancer.

December 8th 2016, 12:07am

IASLC World Conference on Lung Cancer

Treatment with the PD-L1 inhibitor atezolizumab significantly improved overall survival compared to standard chemotherapy in patients with non–small lung cancer who progressed on platinum-based chemotherapy.

December 7th 2016, 11:56pm

IASLC World Conference on Lung Cancer

Patients with non–small cell lung cancer treated in the pembrolizumab arm of the KEYNOTE-024 trial experienced improved quality of life compared with patients who were treated with standard chemotherapy.

December 7th 2016, 11:41pm

IASLC World Conference on Lung Cancer

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

December 7th 2016, 11:22pm

San Antonio Breast Cancer Symposium

The addition of everolimus (Afinitor) to fulvestrant (Faslodex) significantly improved progression-free survival rates in postmenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.

December 7th 2016, 11:13pm

IASLC World Conference on Lung Cancer

Suresh S. Ramalingam, MD, professor, Department of Hematology and Medical Oncology, Deputy Director, Winship Cancer Institute of Emory University, discusses the role of osimertinib in the treatment of patients with EGFR T790M-positive advanced non-small cell lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

December 7th 2016, 11:09pm

ASH Annual Meeting and Exposition

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

December 7th 2016, 6:36am

ASH Annual Meeting and Exposition

Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.

December 7th 2016, 6:26am

ASH Annual Meeting and Exposition

An FDA-approved blood cancer drug has demonstrated encouraging findings, including an overall response rate of 67%, in treatment of patients with chronic graft-versus-host-disease that was not resolved by corticosteroids.

December 7th 2016, 5:56am

ASH Annual Meeting and Exposition

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.

December 7th 2016, 3:10am

IASLC World Conference on Lung Cancer

Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy.

December 7th 2016, 1:06am

IASLC World Conference on Lung Cancer

Frontline treatment with ceritinib (Zykadia) improved progression-free survival over standard chemotherapy in patients with ALK-rearranged non–small cell lung cancer.

December 6th 2016, 10:46pm

IASLC World Conference on Lung Cancer

Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses the results of the IND.226 trial, in an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

December 6th 2016, 10:20pm

IASLC World Conference on Lung Cancer

Claire Verschraegen, MD, professor of Medical Oncology, University of Vermont Cancer Center, discusses the results of the JAVELIN Solid Tumor trial during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

December 6th 2016, 9:57pm

IASLC World Conference on Lung Cancer

Treatment with icotinib more than doubled intracranial progression-free survival compared with whole brain irradiation combined with standard chemotherapy.

December 6th 2016, 7:19pm

ASH Annual Meeting and Exposition

Subcutaneous delivery of daratumumab was well tolerated with comparable efficacy to the FDA-approved intravenous dose in patients with relapsed/refractory multiple myeloma.

December 6th 2016, 2:13pm

ASH Annual Meeting and Exposition

Adding venetoclax to bortezomib and dexamethasone showed very promising efficacy and acceptable safety for patients with relapsed/refractory multiple myeloma.